odd Jones, Ph.D., has over twenty years of experience in drug discovery and development in both pharmaceutical and biotechnology companies. He is a co-founder for Abide Therapeutics. Prior to Abide, Todd served as Vice President of Chemistry & Enabling Technologies at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) where he had responsibility for establishing, building and guiding Medicinal Chemistry, Biology Enabling Research Technologies (Compound Logistics, Developability, Drug Metabolism & Pharmacokinetics, Genomics and High Throughput Screening), Scale-up Chemistry, Analytical Chemistry, and Computational Chemistry. During Todd’s leadership tenure, the J&JPRD La Jolla site generated over thirty new molecular entities that were accepted into development with more than fifteen advancing into human clinical trials.

 odd Jones, Ph.D., has over twenty years of experience in drug discovery and development in both pharmaceutical and biotechnology companies. He is a co-founder for Abide Therapeutics. Prior to Abide, Todd served as Vice President of Chemistry & Enabling Technologies at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) where he had responsibility for establishing, building and guiding Medicinal Chemistry, Biology Enabling Research Technologies (Compound Logistics, Developability, Drug Metabolism & Pharmacokinetics, Genomics and High Throughput Screening), Scale-up Chemistry, Analytical Chemistry, and Computational Chemistry. During Todd’s leadership tenure, the J&JPRD La Jolla site generated over thirty new molecular entities that were accepted into development with more than fifteen advancing into human clinical trials.